Richard Wagner

21 timestamped statements across 1 collection — auto-found in recorded discussions, each timestamp jumps to the exact moment.

Featured diaries

▶ Ep 14 · 5:10
Our goal is to validate these biomarkers in amniotic fluids in a larger and independent clinical cohort and define 2 to 3 markers that can predict outcomes in CDH cases, and also we want to test whether this marker can be isolated from maternal blood samples instead of amniotic fluid. This would make an ideal biomarker for prenatal CDH outcome prediction.
quote · Congenital Diaphragmatic Hernia
▶ Ep 14 · 3:50
It's important to say that at the time point of amniotic fluid sampling, there was no difference between the two groups. Observed over expected lung to head ratio was similar between survivors and non-survivors. Also, gestational age, liver herniation, or birth weight did not differ between the two groups.
quote · Congenital Diaphragmatic Hernia

Nothing matches these filters — clear the search or widen the filters.

Congenital Diaphragmatic Hernia 21 entries

EUPSA - Circular RNA profiles isolated from amniotic fluidscan distinguish between CDH survivors and non-survivers - Richard Wagner

▶ Ep 14 · 0:21
quote Prenatal diagnosis and prognostication of CDH cases relies currently only on imaging modalities, but sensitivity for CDH cases lies around 70% and remains imperfect in terms of family counseling and prognostication. ↗
▶ Ep 14 · 0:21
clinical Prenatal diagnosis and prognostication of CDH cases relies currently only on imaging modalities, with sensitivity for CDH cases around 70%. ↗
▶ Ep 14 · 1:40
clinical Circular RNAs are an RNA species with a circular shape that is highly stable in biofluids and has potential as biomarkers in several human disease contexts. ↗
▶ Ep 14 · 1:40
quote Circular RNAse is an RNA species with a circular shape that is highly stable in biofluids and again has potential as biomarkers in several human disease contexts. ↗
▶ Ep 14 · 2:10
clinical Circular RNA profiles are significantly altered between CDH and control fetal lungs at two different developmental time points. ↗
▶ Ep 14 · 2:40
clinical The microarray profiling detected approximately 12,000 circular RNAs in fetal lung tissue samples. ↗
▶ Ep 14 · 3:00
clinical An algorithm could successfully cluster CDH lungs and control lungs into two separate groups based on circular RNA profiles at both developmental time points investigated. ↗
▶ Ep 14 · 3:30
clinical Amniotic fluid samples were obtained from CDH cases undergoing fetal tracheal occlusion. ↗
▶ Ep 14 · 3:50
quote It's important to say that at the time point of amniotic fluid sampling, there was no difference between the two groups. Observed over expected lung to head ratio was similar between survivors and non-survivors. Also, gestational age, liver herniation, or birth weight did not differ between the two groups. ↗
▶ Ep 14 · 3:50
clinical At the time point of amniotic fluid sampling, observed over expected lung to head ratio was similar between survivors and non-survivors. ↗
▶ Ep 14 · 4:20
clinical Gestational age, liver herniation, and birth weight did not differ between CDH survivors and non-survivors at the time of amniotic fluid sampling. ↗
▶ Ep 14 · 4:40
clinical Circular RNA profiles isolated from amniotic fluid samples can distinguish between CDH survivors and non-survivors, indicating prognostic value superior to current imaging modalities. ↗
▶ Ep 14 · 4:40
quote when we looked at circular RNA profiles isolated from amniotic fluid samples between survivors and non-survivors, we found that circular RNA profiles can distinguish between the two groups, indicating that they have some prognostic value that is superior to the current imaging modalities. ↗
▶ Ep 14 · 5:10
quote Our goal is to validate these biomarkers in amniotic fluids in a larger and independent clinical cohort and define 2 to 3 markers that can predict outcomes in CDH cases, and also we want to test whether this marker can be isolated from maternal blood samples instead of amniotic fluid. This would make an ideal biomarker for prenatal CDH outcome prediction. ↗
▶ Ep 14 · 5:10
opinion The research goal is to validate these biomarkers in amniotic fluids in a larger and independent clinical cohort and define 2 to 3 markers that can predict outcomes in CDH cases. ↗
▶ Ep 14 · 5:10
opinion The team plans to test whether circular RNA markers can be isolated from maternal blood samples instead of amniotic fluid. ↗
▶ Ep 14 · 6:01
clinical The COVID pandemic impacted the study by limiting patient recruitment and CDH case enrollment. ↗
▶ Ep 14 · 6:30
clinical The initial study was a screening experiment that profiled all detectable circular RNAs in samples. ↗
▶ Ep 14 · 6:50
clinical The team received funding from the Canadian Institutes of Health Research for a multi-center study to increase sample size and validate findings. ↗
▶ Ep 14 · 8:09
clinical The study is not currently powered to stratify cases of syndromic CDH versus non-syndromic CDH or different severity levels. ↗
▶ Ep 14 · 8:09
opinion Based on prior work with circular RNAs in CDH lungs, the researchers believe they have a disease-specific marker. ↗